Recently, a phase I dose-escalation study showed that Chiauranib could simultaneously inhibits angiogenesis-related kinases, AURKB, and chronic inflammation-related kinase CSF-1R and is tested to be tolerable even in advanced solid tumors, especially in NSCLC (4 in 5 patients with disease control) [42]. This evidence concerns the gene CSF1R and non-small cell lung carcinoma.